5.13-5.19 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

This collaboration aims to advance the Phase I/II clinical trials of TG4050, a personalized therapeutic vaccine for patients afflicted with head and neck cancers.

May 18th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The research focused on a trispecific antibody known as SAR441236, developed by ModeX Therapeutics Inc., a subsidiary of OPKO Health.

Elysium Therapeutics has made significant strides in enhancing opioid safety through the successful Phase 1 clinical trial of its O2P™ hydrocodone prodrug.

Grace Science, LLC has initiated a clinical trial for GS-100, a gene therapy developed to treat NGLY1 Deficiency, with the first patient receiving the treatment.

Ankyra Therapeutics has reached a pivotal moment with the commencement of patient dosing in a Phase 1 clinical trial for their drug candidate, ANK-101.

In a recent clinical trial, the use of N-803 in combination with natural killer (NK) cells demonstrated promising results in potentially lowering the viral load for individuals with HIV.

Pfizer has achieved a clinical milestone for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223), triggering a $7 million payment to LAVA.

The study, designated M24-122, is assessing the efficacy and safety of ABBV-303 both as a standalone treatment and in tandem with AbbVie's immunotherapy budigalimab (ABBV-181).

CASI Pharmaceuticals have unveiled promising preliminary data for BI-1206 combined with rituximab in Chinese patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL).

ECUR-506, a gene editing therapy developed through a partnership with Precision BioSciences, Inc.